Sage Therapeutics, Inc. filed an 8-K report with the Securities and Exchange Commission. The filing disclosed that the Board of Directors of Sage Therapeutics has commenced a strategic review process ...

Sage Therapeutics turns down Biogen's offer to buy the remaining stake in the company and is evaluating strategic alternatives to maximize shareholder value.

M&A specialists are eyeing a robust list of U.S. takeover candidates, with a buoyant economy, strong buyer appetite and a ...

M&A specialists are eyeing a robust list of likely US takeover candidates, with a buoyant economy, strong buyer appetite and ...

Sage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of ...

Franklin Financial Services Corporation (the Corporation) , the bank holding company of F&M Trust (the Bank) headquartered in Chambersburg, PA, reported its fourth quarter 2024 and year-to-date 2024 ...

Alithya Group inc. ("Alithya") will disclose on February 13, 2025, the financial results for its fiscal 2025 third quarter ended December 31, 2024. Alithya will host a conference call followed by a ...

Donald Trump continues to make waves in biopharma; Sage rejects Biogen’s unsolicited takeover offer; the obesity space sees ...

While the strategic review process is underway, Sage Therapeutics continues to advance its mission of pioneering solutions to ...